Autoinjectors Market
Autoinjectors Market Analysis by Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, Cardiovascular Disorders, and Diabetes from 2023 to 2033
Analysis of Autoinjectors Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Autoinjectors Market Outlook (2023 to 2033)
The global autoinjectors market size was valued at US$ 59.04 Billion in 2023, and is predicted to reach US$ 260.45 Billion by 2033, growing at a compound annual growth rate (CAGR) of 16% during the forecast period from 2023 to 2033.
Autoinjector is medical device used to deliver a dose of a particular medication. These injections are intended to get beyond the self-administration reluctance of needle-based drug delivery methods. Since autoinjectors are simple to use they can be delivered by untrained individuals or by patients themselves. Most of them are spring-loaded and single-use syringes. Depending on the drug loaded, the site of administration may vary, however, it is often injected into the buttock or thigh.
Being specialized medical tools, auto-injectors can be used to lessen needle stick injuries and assist in easing the needle fear that is extremely frequent among patients. Auto-injectors are chosen over conventional medication administration methods such as traditional injectables because of their many benefits, such as their easy use, greater precision, and reduced discomfort.
Autoinjectors help ensure that the full quantity of medication is administered without discomfort. The market for autoinjectors is expected to expand at an impressive rate during the forecast period due to the simplicity that these autoinjectors offer to patients.
People are choosing numerous advanced treatment methods to manage and treat chronic illnesses as well as to alleviate symptoms as the prevalence of chronic disorders is rapidly spreading across the globe. Traditional drug delivery techniques or systems, however, take a lot of time and are laborious, uncomfortable, and painful.
People are therefore looking for more effective and sophisticated drug delivery devices, such as autoinjectors. The growing tendency of using medical supplies such as insulin at home and the rising prevalence of life-threatening disorders are boosting the autoinjectors market growth.
Autoinjectors are segmented into reusable and disposable autoinjectors. Reusable autoinjectors are further classified into prefilled autoinjectors and empty autoinjectors. Reusable autoinjectors currently dominating the global autoinjectors market share. Due to ease of self-administration, decreased anxiety, and dosage precision, prefilled autoinjectors are increasingly preferred by end users over fillable ones.
By lessening the likelihood of unintentional needle sticks and product exposure, prefilled pharmaceuticals increase patient safety. For patients who need long-term treatment and parenteral drug administration on a daily or weekly basis, prefilled injection is practicable. As a result, patients favour self-administrating devices as they are no longer reliant on doctors for every dosage.
Report Attributes |
Details |
|
Autoinjectors Market Size (2023E) |
US$ 59.04 Billion |
|
Forecasted Market Value (2033F) |
US$ 260.45 Billion |
|
Global Market Growth Rate (2023 to 2033) |
16% CAGR |
|
China Market Growth Rate (2023 to 2033) |
21.5% CAGR |
|
Japan Market Growth Rate (2023 to 2033) |
12% CAGR |
|
Germany Market Growth Rate (2023 to 2033) |
13% CAGR |
|
Canada Market Growth Rate (2023 to 2033) |
14% CAGR |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Market Trends are Expected to Be Profitable for Manufacturers of Autoinjectors?
“Advancements in Designs of Autoinjectors”
Autoinjectors are also called single-shot injectors due to their multiple benefits such as dosage accuracy, easy self-administration, and improved patient satisfaction.
The autoinjector devices’ cutting-edge designs are enhancing drug delivery efficiency. Autoinjectable doses are becoming more popular among patients who need to consume medications on a daily or weekly basis. The rising demand for self-use devices for the treatment and management of different diseases is also boosting the sales of autoinjectors.
Auto-injectors and pen injectors are becoming more popular due to their user-friendly qualities. Also, technological developments have made it possible for autoinjector devices to ensure low error rates for first-time users while also guaranteeing the precise dosage of the medication the patient intends to self-administer.
“Rising Cases of Chronic Disorders across the World”
Rising prevalence of chronic disorders is playing a triggering factor in the increasing demand for autoinjectors. Globally, chronic diseases are a key cause of rising death rates and increasing rates of individuals with disabilities.
- The World Health Organization (WHO) predicted that the majority of chronic diseases account for 60% of the global disease burden each year and 73% of all fatalities globally.
For instance, the prevalence of multiple sclerosis, a chronic autoimmune condition, is rising rapidly in developed nations such as the United States.
- According to research from the National Multiple Sclerosis Society, approximately 1 million Americans were estimated to have multiple sclerosis in 2019.
“Increasing Demand for Advanced Autoinjectors”
Several initiatives by respective governments of emerging countries, expanding point-of-care device demand, and growing public awareness of the advantages of autoinjectors over conventional drug delivery systems are all contributing to the rapid sales of autoinjector devices.
Auto-injectors are a straightforward and streamlined alternative to syringes that allow for drug self-administration. Compared to manual syringes the auto-injectors offer more precise and constant drug dosage.
Furthermore, it is anticipated that the user-friendliness of auto-injectors, rising introductions of novel autoinjectors with improved functionality in the market such as single-design autoinjectors, a greater emphasis on safety and efficacy, and increasing prevalence of diseases such as diabetes, multiple sclerosis, and anaphylaxis will drive autoinjector sales during the forecast period.
What May Affect to Growth of the Sales of Autoinjectors?
“Lengthy Product Approval Process and High Pricing Trends”
The extensive process of research and development for autoinjectors entails the employment of cutting-edge technologies, which raises production costs and yields expensive final products. Autoinjector sales are hampered by such high costs in developing and undeveloped nations where user's purchasing power is constrained.
Furthermore, the lengthy approval processes for many products and the strict regulatory requirements lead to pricey autoinjectors. Also, several product recalls are expected to hamper sales graphs to some extent.
How are New Market Players Performing in This Industry?
“New Companies Focused on Developing Advanced Drug Delivery Options”
To expand their research and development of breakthrough technologies and hasten the release of cutting-edge products, autoinjector start-ups are concentrating on raising fresh funds. To compete with the well-established market players, the new auto-injector producers are also using their funding to create innovative marketing and commercial strategies.
- The creation of therapeutic proteins and monoclonal antibodies that could allow the delivery of biologics by autoinjectors and prefilled syringes was the focus of Elektrofi's biotechnology start-up, for which it has raised US$ 40 billion in June 2022. The extra funding was meant to be applied for the development of a GMP manufacturing line and the promotion of its drug delivery system in clinics.
A detailed study on the start-up ecosystem and new developments is been listed by Fact.MR, a market research and competitive intelligence provider in its latest report on autoinjectors.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
Why is the United States a Lucrative Market for Autoinjector Suppliers?
“Rising Cases of Cancer & Diabetes”
Demand for autoinjectors is expected to expand at a rapid pace in the United States during the projected period. This can be attributed to the aspects such as the rapidly growing prevalence of chronic disorders such as diabetes and cancer, and the high rate of advanced product adoption.
- According to Globocon 2020, there were 612,390 fatalities and 2,281,658 newly diagnosed cancer cases in the United States in 2020.
- Breast cancer had the maximum incidence of all malignancies, with 253,465 cases, followed by lung cancer (227,875), prostate cancer (209,512), and colon cancer (101,809).
In the United States, ailments such as diabetes and anaphylaxis have increased dramatically over time.
- The Centers for Disease Control and Prevention (CDC) estimate that over 37.3 million Americans have diabetes. These patients rely heavily on insulin shots to control their blood sugar levels.
- Anaphylaxis, a potentially fatal allergic reaction, is prevalent in the United States and affects around one in 50 people, according to research by the Asthma and Allergy Foundation of America (AAFA).
Also, the United States market is growing as a result of rising technological improvements, the entry of new competitors, and the quick introduction of innovative products.
- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., announced in April 2020 that AJOVY (fremanezumab-vfrm) autoinjector devices are available in the United States. The anti-CGRP (calcitonin gene-related peptide) precautionary migraine medicine with monthly (225 mg) and quarterly (675 mg) subcutaneous dose options is AJOVY, which is recommended for the preventative treatment of migraine in adults.
What is Aiding the Sales of Autoinjectors in Germany?
“Rapid Advancements in Healthcare Systems”
Sales of autoinjectors in Germany are predicted to evolve at a CAGR of 13% during the next 10 years. This can be due to the rising prevalence of life-threatening diseases, the growing need for needle-free drug delivery devices, and the availability of cutting-edge medication delivery technologies.
In terms of innovation and health, Germany is gaining popularity. The country's increasing focus on patented drug delivery systems and R&D activities is boosting demand for auto-injectors.
Sales of autoinjectors are also expected to increase substantially over the next ten years due to established patient safety rules and the increasing incidences of needle stick accidents.
- A glucagon-prefilled auto-injector pen known as Ogluo® was made available in Germany in November 2022, according to a release from Tetris Pharma Ltd., a division of Arecor Therapeutics plc. In both adults and children with diabetes, the product is used to treat severe hypoglycemia.
Why is Japan Considered an Investment-worthy Market in Asia Pacific?
“Rapidly Growing Rate of Senior Population Leading to Increasing Cases of Orthopedic Conditions”
Nearly one-third of Japan's population is over the age of 65, and this group is heavily influencing the country's healthcare industry trends. Autoinjector demand is expected to increase in the nation over the coming years due to the increasing cases of joint and bone-related health problems, such as rheumatoid arthritis, among the elderly.
The Japanese market is expected to progress at a CAGR of 12% from 2023 to 2033 due to the advancements in injectable drug treatment technologies, developing healthcare infrastructure, and the growing rate of the elderly population.
- A well-known Japanese pharmaceutical manufacturer, Otsuka Pharmaceutical Co. Ltd., declared in June 2022 that an auto-injector dosage form for AJOVY® Subcutaneous Injection 225 mg manufactured by Teva Pharmaceuticals had received regulatory approval for sale in Japan. Otsuka Pharmaceutical is the official distributor of AJOVY in Japan.
Category-wise Analysis
For Which Disease Treatment are Autoinjectors Widely Used?
“Anaphylaxis - A Severe Allergic Issue”
Autoinjectors are used to treat diseases such as rheumatoid arthritis, anaphylaxis, multiple sclerosis, cardiovascular disorders, diabetes, and more.
Anaphylaxis, a potentially fatal allergic reaction, is one of many allergic reactions that are commonly treated with epinephrine autoinjectors. It is anticipated that rising anaphylaxis rates would increase demand for epinephrine autoinjectors (EAIs) as a treatment, as it is typically administered via pre-filled syringes and autoinjectors. This will generate potential opportunities in the autoinjectors market.
Many allergy drugs are delivered using auto-injector syringes since anyone can do it without medical expertise or experience. Sales of autoinjectors for anaphylaxis are predicted to increase at a rapid pace during the forecast period due to the growing need for injectable epinephrine to treat a variety of allergic reactions, including anaphylaxis.
Competitive Landscape
To gain a large client base and earn more revenue shares, key players in the autoinjectors market are developing advanced home-use autoinjectors, and needle-free devices & therapies. Along with this, they are also adopting market strategies such as mergers, collaborations, partnerships, regional expansion, and more.
Fact.MR report reveals detailed information regarding winning strategies such as local supply, product standards, supply chain management, quality control, and more adopted by leading companies in the autoinjectors market to earn more.
- The Qfinity autoinjector platform, a straightforward, reusable, and cost-effective solution for subcutaneous (SC) drug self-administration, was introduced by Jabil Healthcare, a branch of Jabil Inc., in May 2022.
- Stevanato Group S.p.A. inked an exclusive contract for its Aidaptus auto-injector in May 2022 with Owen Mumford Ltd., one of the top producers and innovators of medical devices.
Key Segments of Autoinjectors Industry Research
-
By Disease :
- Rheumatoid Arthritis
- Anaphylaxis
- Multiple Sclerosis
- Cardiovascular Disorders
- Diabetes
-
By Type :
- Disposable Autoinjectors
- Reusable Autoinjectors
-
By Route of Administration :
- Subcutaneous
- Intramuscular
-
By Type of Molecule :
- Monoclonal Antibodies
- Peptides, Proteins
- Small Molecules
-
By End User :
- Home Care Settings
- Hospitals & Clinics
- Ambulatory Care Settings
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Rise in Expenditure 4.1.2. Increased Per Capita Expenditure 4.2. Forecast Factors - Relevance & Impact 4.2.1. Product in Pipeline 4.2.2. Regulatory Scenario 4.2.3. Mergers and Acquisitions 4.2.4. Collaborative Agreements 4.2.5. Value Chain 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 4.4. COVID19 Crisis Analysis 4.4.1. Current COVID19 Statistics and Probable Future Impact 4.4.2. Current GDP Projection and Probable Impact 4.4.3. Current Economic Projection as Compared to 2008 Economic analysis 4.4.4. COVID19 and Impact Analysis 4.4.4.1. Revenue By Disease 4.4.4.2. Revenue By Route of Administration 4.4.4.3. Revenue By Type 4.4.4.4. Revenue By Type of Molecule 4.4.4.5. Revenue By End User 4.4.4.6. Revenue By Country 4.4.5. 2020 Market Scenario 4.4.6. Quarter by Quarter Forecast 4.4.7. Projected Recovery Quarter 4.4.8. Recovery Scenario – Short term, Midterm and Long Term Impact 5. Market Context 5.1. Adoption and Usage Analysis 5.2. Market Evolution 5.3. Product Vs Route of Administration Matrix 5.4. Regulatory Scenario 5.5. Parent Market Analysis 5.6. Key Promotional Strategies by Market Players 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis By Disease 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Disease, 2018 to 2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease, 2023 to 2033 8.3.1. Rheumatoid Arthritis 8.3.2. Anaphylaxis 8.3.3. Multiple Sclerosis 8.3.4. Cardiovascular Disorders 8.3.5. Diabetes 8.4. Market Attractiveness Analysis By Disease 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Type 9.1. Introduction / Key Findings Type Size, 2018 to 2022 9.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2023 to 2033 9.2.1. Disposable Autoinjectors 9.2.2. Reusable Autoinjectors 9.3. Market Attractiveness Analysis By Type 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Route of Administration 10.1. Introduction / Key Findings Route of Administration Size, 2018 to 2022 10.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2023 to 2033 10.2.1. Subcutaneous 10.2.2. Intramuscular 10.3. Market Attractiveness Analysis By Route of Administration 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Type of Molecule 11.1. Introduction / Key Findings Size, 2018 to 2022 11.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type of Molecule, 2023 to 2033 11.2.1. Monoclonal Antibodies 11.2.2. Peptides, Proteins 11.2.3. Small Molecules 11.3. Market Attractiveness Analysis By Type of Molecule 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by End User 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By End User, 2018 to 2022 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2023 to 2033 12.3.1. Home Care Settings 12.3.2. Hospitals & Clinics 12.3.3. Ambulatory Care Settings 12.4. Market Attractiveness Analysis By End User 13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2018 to 2022 13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. United States 14.3.1.2. Canada 14.3.2. By Disease 14.3.3. By Type 14.3.4. By Route of Administration 14.3.5. By Type of Molecule 14.3.6. By End User 14.4. Market Attractiveness Analysis 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. Rest of Europe 15.3.2. By Disease 15.3.3. By Type 15.3.4. By Route of Administration 15.3.5. By Type of Molecule 15.3.6. By End User 15.4. Market Attractiveness Analysis 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. South Africa 16.3.1.3. Rest of Middle East and Africa 16.3.2. By Disease 16.3.3. By Type 16.3.4. By Route of Administration 16.3.5. By Type of Molecule 16.3.6. By End User 16.4. Market Attractiveness Analysis 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. Rest of the World Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Disease 17.3.2. By Type 17.3.3. By Route of Administration 17.3.4. By Type of Molecule 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. Key and Emerging Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. United States Market Analysis 18.2.1. By Disease 18.2.2. By Type 18.2.3. By Route of Administration 18.2.4. By Type of Molecule 18.2.5. By End User 18.3. Canada Market Analysis 18.3.1. By Disease 18.3.2. By Type 18.3.3. By Route of Administration 18.3.4. By Type of Molecule 18.3.5. By End User 18.4. United Kingdom Market Analysis 18.4.1. By Disease 18.4.2. By Type 18.4.3. By Route of Administration 18.4.4. By Type of Molecule 18.4.5. By End User 18.5. Germany Market Analysis 18.5.1. By Disease 18.5.2. By Type 18.5.3. By Route of Administration 18.5.4. By Type of Molecule 18.5.5. By End User 18.6. France Market Analysis 18.6.1. By Disease 18.6.2. By Type 18.6.3. By Route of Administration 18.6.4. By Type of Molecule 18.6.5. By End User 18.7. Italy Market Analysis 18.7.1. By Disease 18.7.2. By Type 18.7.3. By Route of Administration 18.7.4. By Type of Molecule 18.7.5. By End User 18.8. Spain Market Analysis 18.8.1. By Disease 18.8.2. By Type 18.8.3. By Route of Administration 18.8.4. By Type of Molecule 18.8.5. By End User 18.8.6. By End User 18.9. GCC Countries Market Analysis 18.9.1. By Disease 18.9.2. By Type 18.9.3. By Route of Administration 18.9.4. By Type of Molecule 18.9.5. By End User 18.10. South Africa Market Analysis 18.10.1. By Disease 18.10.2. By Type 18.10.3. By Route of Administration 18.10.4. By Type of Molecule 18.10.5. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Product foot print by Players 19.4.3. Channel Foot Print by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. AbbVie, Inc. 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Analyst Commentary 20.3.1.4. Key Financials 20.3.1.5. Recent Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Strategy 20.3.1.7.3. Channel Strategy 20.3.2. Amgen, Inc. 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Analyst Commentary 20.3.2.4. Key Financials 20.3.2.5. Recent Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Antares Pharma, Inc. 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Analyst Commentary 20.3.3.4. Key Financials 20.3.3.5. Recent Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Becton, Dickinson and Company 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Analyst Commentary 20.3.4.4. Key Financials 20.3.4.5. Recent Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Consort Medical PLCEli 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Analyst Commentary 20.3.5.4. Key Financials 20.3.5.5. Recent Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Lilly and Company 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Analyst Commentary 20.3.6.4. Key Financials 20.3.6.5. Recent Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Haselmeier GmbH 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Analyst Commentary 20.3.7.4. Key Financials 20.3.7.5. Recent Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Mylan NV 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Analyst Commentary 20.3.8.4. Key Financials 20.3.8.5. Recent Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Owen Mumford Ltd. 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Analyst Commentary 20.3.9.4. Key Financials 20.3.9.5. Recent Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Strategy 20.3.9.7.3. Channel Strategy 20.3.10. SHL Group 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Analyst Commentary 20.3.10.4. Key Financials 20.3.10.5. Recent Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Product Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Teva Pharmaceutical Industries Ltd. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Analyst Commentary 20.3.11.4. Key Financials 20.3.11.5. Recent Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Product Strategy 20.3.11.7.3. Channel Strategy 20.3.12. Ypsomed AG 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Analyst Commentary 20.3.12.4. Key Financials 20.3.12.5. Recent Developments 20.3.12.6. Sales Footprint 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategy 20.3.12.7.2. Product Strategy 20.3.12.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 02: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 03: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 04: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Molecule
Table 05: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 06: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Molecule Age Group
Table 07: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 08: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 09: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 10: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 11: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 12: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Molecule
Table 13: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 17: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 18: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Molecule
Table 19: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 20: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 21: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 22: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 23: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 24: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Molecule
Table 25: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 26: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 27: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 28: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 29: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Molecule
Table 30: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 02: Global Market Absolute $ Opportunity, 2023 to 2033
Figure 03: Global Market Share Analysis (%), By Disease, 2023 & 2033
Figure 04: Global Market Y-o-Y Analysis (%), By Disease, 2023 to 2033
Figure 05: Global Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 06: Global Market Share Analysis (%), By Type, 2023 & 2033
Figure 07: Global Market Y-o-Y Analysis (%), By Type, 2023 to 2033
Figure 08: Global Market Attractiveness Analysis By Type, 2023 to 2033
Figure 09: Global Market Share Analysis (%), By Route of Administration, 2023 & 2033
Figure 10: Global Market Y-o-Y Analysis (%), By Route of Administration, 2023 to 2033
Figure 11: Global Market Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 12: Global Market Share Analysis (%), By Type of Molecule, 2023 & 2033
Figure 13: Global Market Y-o-Y Analysis (%), By Type of Molecule, 2023 to 2033
Figure 14: Global Market Attractiveness Analysis By Type of Molecule, 2023 to 2033
Figure 15: Global Market Share Analysis (%), By End User, 2023 & 2033
Figure 16: Global Market Y-o-Y Analysis (%), By End User , 2023 to 2033
Figure 17: Global Market Attractiveness Analysis, By End User, 2023 to 2033
Figure 18: Global Market Share Analysis (%), By Type of Molecule Age Group, 2023 & 2033
Figure 19: Global Market Y-o-Y Analysis (%), By Type of Molecule Age Group, 2023 to 2033
Figure 20: Global Market Attractiveness Analysis By Type of Molecule Age Group, 2023 to 2033
Figure 21: Global Market Share Analysis (%), By Region, 2023 & 2033
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2023 to 2033
Figure 23: Global Market Attractiveness Analysis, By Region, 2023 to 2033
Figure 24: North America Market Value Share, By Disease, 2023 (E)
Figure 25: North America Market Value Share, By Route of Administrations 2023 (E)
Figure 26: North America Market Value Share, By Type, 2023 (E)
Figure 27: North America Market Value Share, By Type of Molecule, 2023 (E)
Figure 28: North America Market Value Share, By End User, 2023 (E)
Figure 29: North America Market Value Share, By Country, 2023 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 31: North America Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 32: North America Market Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 33: North America Market Attractiveness Analysis By Type, 2023 to 2033
Figure 34: North America Market Attractiveness Analysis By Type of Molecule, 2023 to 2033
Figure 35: North America Market Attractiveness Analysis By End User, 2023 to 2033
Figure 36: North America Market Attractiveness Analysis By Country, 2023 to 2033
Figure 37: Europe Market Value Share, By Disease, 2023 (E)
Figure 38: Europe Market Value Share, By Route of Administrations 2023 (E)
Figure 39: Europe Market Value Share, By Type, 2023 (E)
Figure 40: Europe Market Value Share, By Type of Molecule, 2023 (E)
Figure 41: Europe Market Value Share, By End User, 2023 (E)
Figure 42: Europe Market Value Share, By Country, 2023 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 44: Europe Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 45: Europe Market Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 46: Europe Market Attractiveness Analysis By Type, 2023 to 2033
Figure 47: Europe Market Attractiveness Analysis By Type of Molecule, 2023 to 2033
Figure 48: Europe Market Attractiveness Analysis By Type, 2023 to 2033
Figure 49: Europe Market Attractiveness Analysis By Country, 2023 to 2033
Figure 50: Middle East and Africa Market Value Share, By Disease, 2023 (E)
Figure 51: Middle East and Africa Market Value Share, By Route of Administration, 2023 (E)
Figure 52: Middle East and Africa Market Value Share, By Type, 2023 (E)
Figure 53: Middle East and Africa Market Value Share, By Type of Molecule, 2023 (E)
Figure 54: Middle East and Africa Market Value Share, By End User, 2023 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2023 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 57: Middle East and Africa Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 58: Middle East and Africa Market Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 59: Middle East and Africa Market Attractiveness Analysis By Type, 2023 to 2033
Figure 60: Middle East and Africa Market Attractiveness Analysis By Type of Molecule, 2023 to 2033
Figure 61: Middle East and Africa Market Attractiveness Analysis By End User, 2023 to 2033
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2023 to 2033
Figure 63: Rest of the World Market Value Share, By Disease, 2023 (E)
Figure 64: Rest of the World Market Value Share, By Route of Administrations 2023 (E)
Figure 65: Rest of the World Market Value Share, By Type, 2023 (E)
Figure 66: Rest of the World Market Value Share, By Type of Molecule, 2023 (E)
Figure 67: Rest of the World Market Value Share, By End User, 2023 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 69: Rest of the World Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 70: Rest of the World Market Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 71: Rest of the World Market Attractiveness Analysis By Type, 2023 to 2033
Figure 72: Rest of the World Market Attractiveness Analysis By Type of Molecule, 2023 to 2033
Figure 73: Rest of the World Market Attractiveness Analysis By End User, 2023 to 2033
Figure 74: United States Market Value Share, By Disease, 2023 & 2033
Figure 75: United States Market Value Share, By Route of Administration, 2023 & 2033
Figure 76: United States Market Value Share, By Type, 2020 &2030
Figure 77: United States Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 78: United States Market Value Share, By End User, 2023 & 2033
Figure 79: United States Market Value Analysis (US$ Mn), 2023 & 2033
Figure 80: Canada Market Value Share, By Disease, 2023 & 2033
Figure 81: Canada Market Value Share, By Route of Administration, 2023 & 2033
Figure 82: Canada Market Value Share, By Type, 2023 & 2033
Figure 83: Canada Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 84: Canada Market Value Share, By End User, 2023 & 2033
Figure 85: Canada Market Value Analysis (US$ Mn), 2023 & 2033
Figure 86: United Kingdom Market Value Share, By Disease, 2023 & 2033
Figure 87: United Kingdom Market Value Share, By Route of Administration, 2023 & 2033
Figure 88: United Kingdom Market Value Share, By Type, 2023 & 2033
Figure 89: United Kingdom Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 90: United Kingdom Market Value Share, By End User, 2023 & 2033
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2023 & 2033
Figure 92: Germany Market Value Share, By Disease, 2023 & 2033
Figure 93: Germany Market Value Share, By Route of Administration, 2023 & 2033
Figure 94: Germany Market Value Share, By Type, 2023 & 2033
Figure 95: Germany Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 96: Germany Market Value Share, By End User, 2023 & 2033
Figure 97: Germany Market Value Analysis (US$ Mn), 2023 & 2033
Figure 98: France Market Value Share, By Disease, 2023 & 2033
Figure 99: France Market Value Share, By Route of Administration, 2023 & 2033
Figure 100: France Market Value Share, By Type, 2023 & 2033
Figure 101: France. Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 102: France Market Value Share, By End User, 2023 & 2033
Figure 103: France Market Value Analysis (US$ Mn), 2023 & 2033
Figure 104: Italy Market Value Share, By Disease, 2023 & 2033
Figure 105: Italy Market Value Share, By Route of Administration, 2023 & 2033
Figure 106: Italy Market Value Share, By Type, 2023 & 2033
Figure 107: Italy Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 108: Italy Market Value Share, By End User, 2023 & 2033
Figure 109: Italy Market Value Analysis (US$ Mn), 2023 & 2033
Figure 110: Spain Market Value Share, By Disease, 2023 & 2033
Figure 111: Spain Market Value Share, By Route of Administration, 2023 & 2033
Figure 112: Spain Market Value Share, By Type, 2023 & 2033
Figure 113: Spain Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 114: Spain Market Value Share, By End User, 2023 & 2033
Figure 115: Spain Market Value Analysis (US$ Mn), 2023 & 2033
Figure 116: GCC Countries. Market Value Share, By Disease, 2023 & 2033
Figure 117: GCC Countries Market Value Share, By Route of Administration, 2023 & 2033
Figure 118: GCC Countries Market Value Share, By Type, 2023 & 2033
Figure 119: GCC Countries Market Value Share, By Type of Molecule, 2023 & 2033
Figure 120: GCC Countries Market Value Share, By End User, 2023 & 2033
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2023 & 2033
Figure 122: South Africa Market Value Share, By Disease, 2023 & 2033
Figure 123: South Africa Market Value Share, By Route of Administration, 2023 & 2033
Figure 124: South Africa Market Value Share, By Type, 2023 & 2033
Figure 125: South Africa Market Value Share, By Type of Molecule Age Group, 2023 & 2033
Figure 126: South Africa Market Value Share, By End User, 2023 & 2033
Figure 127: South Africa Market Value Analysis (US$ Mn), 2023 & 2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the market value of autoinjectors in 2023?
The global autoinjectors market is valued at US$ 59.04 billion in 2023.
What is the expected growth rate of the autoinjectors market?
Global demand for autoinjectors is predicted to increase at a CAGR of 16% from 2023 to 2033.
How big will the market for autoinjectors be by 2033?
The market for autoinjectors is projected to reach US$ 260.45 billion by 2033.
What are the top trends in the autoinjectors market?
Developments in the design of autoinjectors and rising prevalence of chronic illnesses are driving market growth.
Which are the top industry players in the global autoinjectors market?
AbbVie, Inc., Amgen, Inc., Antares Pharma, Inc., and Becton, Dickinson and Company are leading manufacturers of autoinjectors.
Autoinjectors Market